{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:26:00Z","timestamp":1792571160799,"version":"4.5.0"},"reference-count":40,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"unspecified","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n\t  <jats:sec id=\"S0924270825000067_as1\">\n\t    <jats:title>Introduction:<\/jats:title>\n\t    <jats:p>Extant literature implicates the role of glucagon-like peptide-1 (GLP-1) and GLP-1 receptor agonists (GLP-1RAs) on modulating alcohol-associated behaviours, with a particular emphasis of these agents on neural circuits subserving reward and appetite control. Herein, we explore the potential effects of GLP-1RAs on alcohol-associated behaviours in brain regions implicated in reward processing facilitating the repurposing of these agents for the treatment and prevention of problematic drinking. Understanding how GLP-1\u2019s analogues interact with alcohol-related behaviours may underscore the development of therapeutic strategies for alcohol use disorder (AUD) and those with comorbid metabolic disorders.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270825000067_as2\">\n\t    <jats:title>Methods:<\/jats:title>\n\t    <jats:p>A systematic review was conducted, wherein relevant literature was identified through Web of Science, PubMed, and OVID (MedLINE, Embase, AMED, PsycInfo, JBI EBP) from database inception to October 27th, 2024. Preclinical and clinical studies examining the association between GLP-1RAs and alcohol-related behaviours were assessed.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270825000067_as3\">\n\t    <jats:title>Results:<\/jats:title>\n\t    <jats:p>Preclinical studies (<jats:italic>n<\/jats:italic> = 19) indicate that GLP-1RAs attenuate alcohol-related behaviours, with exenatide demonstrating significant dose-dependent effects in high alcohol-consuming phenotypes. Semaglutide and liraglutide are associated with reduced alcohol intake, though their effects were often transient. In human studies (<jats:italic>n<\/jats:italic> = 2) with AUD, semaglutide significantly reduced alcohol consumption, while exenatide showed mixed results, with reductions in alcohol drinking within high BMI subpopulations.<\/jats:p>\n\t  <\/jats:sec>\n\t  <jats:sec id=\"S0924270825000067_as4\">\n\t    <jats:title>Discussion:<\/jats:title>\n\t    <jats:p>Extant preclinical and clinical literature provides preliminary support for the potential therapeutic role of GLP-1RAs in attenuating alcohol consumption and preference. There is a need for large well controlled studies evaluating the effect of GLP-1RAs as a treatment strategy for behavioural modifications in individuals living with alcohol use disorder.<\/jats:p>\n\t  <\/jats:sec>","DOI":"10.1017\/neu.2025.6","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T08:02:52Z","timestamp":1739952172000},"update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":30,"title":["A systematic review on the role of glucagon-like peptide-1 receptor agonists on alcohol-related behaviors: potential therapeutic strategy for alcohol use disorder"],"prefix":"10.1017","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3238-696X","authenticated-orcid":false,"given":"Yang Jing","family":"Zheng","sequence":"first","affiliation":[{"name":"Brain and Cognition Discovery Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystaleene","family":"Soegiharto","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8786-1550","authenticated-orcid":false,"given":"Hezekiah C.T.","family":"Au","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Valentino","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gia Han","family":"Le","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation"},{"name":"University Health Network"},{"name":"University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Wong","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation"},{"name":"University Health Network"},{"name":"University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla M.","family":"Teopiz","sequence":"additional","affiliation":[{"name":"Brain and Cognition Discovery Foundation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeho Greg","family":"Rhee","sequence":"additional","affiliation":[{"name":"Yale School of Medicine"},{"name":"University of Connecticut School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan F.","family":"Guillen-Burgos","sequence":"additional","affiliation":[{"name":"Faculty of Medicine"},{"name":"Center for Clinical and Translational Research"},{"name":"Hospital Universitario San Ignacio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cao","sequence":"additional","affiliation":[{"name":"Southwest University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-2523","authenticated-orcid":false,"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[{"name":"University of Toronto"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"key":"S0924270825000067_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.11.019"},{"key":"S0924270825000067_ref11","doi-asserted-by":"publisher","DOI":"10.1080\/02699052.2019.1587000"},{"key":"S0924270825000067_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-023-04093-6"},{"key":"S0924270825000067_ref32","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.68"},{"key":"S0924270825000067_ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01113-9"},{"key":"S0924270825000067_ref7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249710"},{"key":"S0924270825000067_ref12","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2020.614884"},{"key":"S0924270825000067_ref29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061965"},{"key":"S0924270825000067_ref30","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13199"},{"key":"S0924270825000067_ref24","first-page":"1","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the food and drug administration adverse event reporting system (FAERS)","volume":"23","author":"McIntyre","year":"2023","journal-title":"Expert Opinion on Drug Safety"},{"key":"S0924270825000067_ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-00923-1"},{"key":"S0924270825000067_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14437"},{"key":"S0924270825000067_ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01931-z"},{"key":"S0924270825000067_ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-023-06367-x"},{"key":"S0924270825000067_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104642"},{"key":"S0924270825000067_ref22","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2430306"},{"key":"S0924270825000067_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2020.104772"},{"key":"S0924270825000067_ref2","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000620"},{"key":"S0924270825000067_ref23","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230922"},{"key":"S0924270825000067_ref38","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12295"},{"key":"S0924270825000067_ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.599646"},{"key":"S0924270825000067_ref17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159863"},{"key":"S0924270825000067_ref27","article-title":"PRISMA 2020 Explanation and elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"British Medical Journal"},{"key":"S0924270825000067_ref18","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1133472"},{"key":"S0924270825000067_ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-00238-8"},{"key":"S0924270825000067_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.02.020"},{"key":"S0924270825000067_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2024.114622"},{"key":"S0924270825000067_ref26","unstructured":"National Institute of Health (2013) Study Quality Assessment Tools. National Heart Lung and Blood Institute, U.S. Department of Health and Human Services. Available at www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools (accessed 10 November 2024)."},{"key":"S0924270825000067_ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0016-2"},{"key":"S0924270825000067_ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-018-5089-z"},{"key":"S0924270825000067_ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2019.02.006"},{"key":"S0924270825000067_ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.10.062"},{"key":"S0924270825000067_ref31","unstructured":"Systematic review management (2023) Covidence. Available at https:\/\/www.covidence.org\/ (accessed 5 October 2024)."},{"key":"S0924270825000067_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2017.07.014"},{"key":"S0924270825000067_ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48267-2"},{"key":"S0924270825000067_ref35","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02907-6"},{"key":"S0924270825000067_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-024-06637-2"},{"key":"S0924270825000067_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2012.11.009"},{"key":"S0924270825000067_ref6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.170671"},{"key":"S0924270825000067_ref15","first-page":"43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270825000067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:48:46Z","timestamp":1759848526000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270825000067\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":40,"alternative-id":["S0924270825000067"],"URL":"https:\/\/doi.org\/10.1017\/neu.2025.6","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"\u00a9 The Author(s), 2025. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"e51"}}